Predicting PD-L1 in Lung Adenocarcinoma Using 18F-FDG PET/CT Radiomic Features
Diagnostics · 24.02.2025 · 15 (5) · 543
DOI: 10.3390/diagnostics15050543 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 24.02.2025. Verfasst von Huiyuan Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijin…. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: This study aims to retrospectively analyze the clinical and imaging data of 101 patients with lung adenocarcinoma who underwent [18F]FDG PET/CT examination and were pathologically confirmed in the Department of Nuclear Medicine at Peking University Cancer Hospital. This study explores the predictive value and important features of [18F]FDG PET/CT radiomics for PD-L1 expression levels in lung adenocarcinoma patients, assisting in screening patients who may benefit from immunotherapy.
Methods
101 patients with histologically confirmed lung adenocarcinoma who received pre-treatment [18F] FDG PET/CT were included. Among them, 44 patients were determined to be PD-L1 positive and 57 patients were determined to be PD-L1 negative based on immunohistochemical assays. Clinical data, PET/CT radiomics parameters, conventional metabolic parameters, and observed CT characteristics were included in the modeling. Random Forest was used in feature denoising, while Forward Stepwise Regression and the Least Absolute Shrinkage and Selection Operator were used in feature selection. Models based on Tree, Discriminant, Logistic Regression, and Support Vector Machine were trained and evaluatedto explore the value of clinical data, PET/CT radiomics parameters, conventional metabolic parameters, and observed CT characteristics.
Results
All models showed some predictive ability in distinguishing PD-L1 positive from PD-L1 negative samples. Among the multimodal imaging, clinical data were incorporated into the models, with clinical stage and gender selected by Forward Stepwise Regression, while clinical stage, smoking history, and gender were selected by LASSO. When incorporating clinical data and thin-section CT-derived images into the models, nodular type, spiculation, and CT Shape Flatness were selected by Forward Stepwise Regression, while nodular type and spiculation were selected by LASSO. When incorporating clinical data, PET/CT radiomics, observed CT characteristics, and conventional metabolic information. Forward Stepwise Regression selected TLGlean, MTV, nodule component, PET Shape Sphericity, while LASSO selected SULmax, MTV, nodular type, PET Shape Sphericity, and spiculation.
Conclusions
The integration of clinical data, PET/CT radiomics, and conventional metabolic parameters effectively predicted PD-L1 expression, thereby assisting the selection of patients who would benefit from immunotherapy. Observed CT characteristics and conventional metabolic information play an important role in predicting PD-L1 expression levels.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluat…
- United Imaging Healthcare Group, Central Research Institute, Shanghai 201900, China.
ORCID-Profile: Xiangxi Meng, Yang Liu
Zitieren
APA
Zhang, H., Meng, X., Wang, Z., Zhou, X., Liu, Y., & Li, N. (2025). Predicting PD-L1 in Lung Adenocarcinoma Using 18F-FDG PET/CT Radiomic Features. Diagnostics, 15(5), 543. https://doi.org/10.3390/diagnostics15050543
Vancouver
Zhang H, Meng X, Wang Z, Zhou X, Liu Y, Li N. Predicting PD-L1 in Lung Adenocarcinoma Using 18F-FDG PET/CT Radiomic Features. Diagnostics. 2025;15(5):543. doi:10.3390/diagnostics15050543
BibTeX
@article{Zhang2025,
author = {Zhang, Huiyuan and Meng, Xiangxi and Wang, Zhe and Zhou, Xin and Liu, Yang and Li, Nan},
title = {Predicting PD-L1 in Lung Adenocarcinoma Using 18F-FDG PET/CT Radiomic Features},
journal = {Diagnostics},
year = {2025},
volume = {15},
number = {5},
pages = {543},
doi = {10.3390/diagnostics15050543}
}
EUVIMED